Factor II activity measures how well prothrombin, a clotting protein made by the liver, works in the blood. Prothrombin is needed to make thrombin, the enzyme that helps turn fibrinogen into fibrin so a stable clot can form. A low factor II activity result points toward reduced clotting ability and a higher bleeding risk, especially when the level is very low or when other clotting factors are also reduced. A high result is less commonly the main finding, but it can appear with increased prothrombin levels and is sometimes discussed in the wider evaluation of clotting risk.
Most laboratories report factor II activity as a percentage of normal pooled plasma. Adult reference ranges vary by lab, so the range printed beside the result is the one to use. Interpretation also depends on symptoms, medicines, PT/INR, aPTT, liver function, vitamin K status, and whether the result fits a personal or family bleeding history.
- Factor II activity is usually reported as a percentage, with many adult reference ranges falling around 75–150% or 50–200%, depending on the laboratory method.
- Low factor II activity means prothrombin is reduced or not working well, which can prolong PT and sometimes aPTT and raise bleeding risk.
- Common acquired causes of low factor II include warfarin, vitamin K deficiency, liver disease, severe malabsorption, DIC, and some inhibitors.
- Inherited factor II deficiency is extremely rare and usually causes more bleeding when activity is well below normal, especially below about 10–30%.
- A normal factor II activity result does not rule out the prothrombin G20210A mutation; that clot-risk variant needs a genetic test.
- Follow-up often includes PT/INR, aPTT, mixing study, liver tests, vitamin K assessment, and other factor activity tests.
Table of Contents
- What Factor II Activity Measures
- Normal Range and Reference Values
- How to Read Your Result
- Low Factor II Activity
- High Factor II Activity
- Testing Process and Preparation
- Follow-Up Tests and Next Steps
- When Results Need Prompt Attention
What Factor II Activity Measures
Factor II activity measures the working function of prothrombin, also called clotting factor II. Prothrombin is a vitamin K-dependent clotting factor made in the liver. When the clotting system activates, factor Xa and factor Va help convert prothrombin into thrombin. Thrombin then helps convert fibrinogen into fibrin, which strengthens the clot.
A factor II activity test is different from a simple amount test. It does not only ask, “How much prothrombin is present?” It asks whether the patient’s plasma performs factor II’s clotting job in a lab system. Most results are expressed as a percentage compared with normal pooled plasma. A result of 100% means the sample behaves like the lab’s normal reference plasma for that assay.
Factor II belongs to the “common pathway” of coagulation. Problems in this pathway can affect both the prothrombin time and the activated partial thromboplastin time, although PT is often more sensitive to factor II, VII, and X changes than aPTT. A low factor II result therefore fits best when reviewed with the whole clotting pattern, not as an isolated number.
Clinicians order factor II activity when they need to explain abnormal clotting tests or bleeding symptoms. Common reasons include:
- unexplained prolonged PT, INR, or aPTT
- easy bruising, frequent nosebleeds, heavy menstrual bleeding, or bleeding after dental work or surgery
- suspected vitamin K deficiency
- liver disease with abnormal clotting tests
- suspected rare inherited factor II deficiency
- evaluation of acquired inhibitors, including lupus anticoagulant-hypoprothrombinemia syndrome
- complex anticoagulant situations, especially when warfarin or direct oral anticoagulants affect interpretation
The name “prothrombin” causes confusion because two very different issues involve the same protein. Factor II activity tests clotting function. The prothrombin G20210A mutation test looks for an inherited gene variant linked to increased clotting risk. A person with the mutation usually needs genetic testing for confirmation; a factor II activity test alone is not the right screening test for that variant.
Normal Range and Reference Values
Adult factor II activity is commonly considered normal when it falls within the laboratory’s stated reference interval. Many labs use an adult range near 75–145%, 86–150%, or a broader range such as 50–200% of normal pooled plasma. These differences reflect assay design, reagents, calibration, population data, and reporting practices.
Use the reference interval printed on the report before comparing the result with any general range. A result of 70% might be slightly low at one lab and normal at another. A result of 150% might be high in one system and still within range in another.
| Reported value | Common interpretation | Important context |
|---|---|---|
| About 75–150% | Typical adult reference range used by some specialty labs | Small differences near the edges often need repeat testing or clinical correlation. |
| About 50–200% | Broad normal range used by some patient-facing and clinical references | Useful as a general guide, but less specific than the lab’s own interval. |
| Below the lower limit | Reduced factor II activity | Bleeding risk depends on how low it is, symptoms, and whether other factors are low. |
| Above the upper limit | Increased factor II activity | Usually interpreted with clotting history, inflammation, hormones, pregnancy, and genetic risk. |
Newborns and infants have lower levels of several vitamin K-dependent clotting factors than adults. Factor II activity in a newborn can be below the adult reference range without meaning the child has an inherited factor II disorder. Pediatric interpretation requires age-specific reference intervals, especially in the first 6 months of life.
Percentage, U/dL, IU/dL, and U/mL
Most factor activity tests use percentage units because they compare the patient’s activity with normal pooled plasma. In many lab systems, 100% is equivalent to 100 U/dL or 100 IU/dL. The same result can also be written as 1.0 U/mL or 1.0 IU/mL. That means 50% roughly equals 50 U/dL or 0.50 U/mL.
Do not convert units unless the report clearly uses comparable calibration. Some factor assays use specific reference standards, and specialized coagulation labs sometimes include interpretive comments that matter more than the raw conversion.
Normal does not always mean no clotting disorder
A normal factor II activity result means prothrombin function looked normal in that test system. It does not rule out every clotting or bleeding problem. Platelet disorders, von Willebrand disease, fibrinogen problems, factor XIII deficiency, mild factor deficiencies, medication effects, and vessel or connective tissue conditions can cause bleeding symptoms even when factor II activity is normal.
A normal factor II activity result also does not exclude the prothrombin G20210A gene variant. That variant is evaluated with a DNA-based test, not with a standard factor II activity assay.
How to Read Your Result
A factor II activity result becomes meaningful when it is matched to the reason the test was ordered. The same number can carry different weight in a person with no symptoms, a person taking warfarin, a person with cirrhosis, and a child with lifelong bleeding symptoms.
Start with four details on the report:
- The numeric result and units.
- The laboratory’s reference range.
- Whether the specimen or assay had limitations.
- Related clotting tests from the same blood draw, especially PT, INR, and aPTT.
A mildly low factor II result often points to an acquired issue, especially when factors VII, IX, and X are also reduced. Because these factors depend on vitamin K and liver production, patterns across several factors help separate vitamin K deficiency, warfarin effect, liver disease, and rare inherited deficiencies.
A very low isolated factor II result raises concern for congenital factor II deficiency or an acquired inhibitor pattern. Inherited factor II deficiency is rare, so clinicians usually exclude common acquired causes first.
| Pattern | What it often suggests | Typical follow-up |
|---|---|---|
| Normal factor II with normal PT/aPTT | Factor II deficiency is unlikely | Look for non-factor causes if bleeding symptoms continue. |
| Low factor II with prolonged PT | Vitamin K deficiency, warfarin effect, liver disease, or factor II deficiency | Review medications, diet, liver tests, and other vitamin K-dependent factors. |
| Low factor II with prolonged PT and aPTT | Common pathway factor reduction, severe deficiency, liver disease, DIC, or anticoagulant effect | Check factor V, X, fibrinogen, D-dimer, mixing study, and anticoagulant exposure. |
| Low factor II with lupus anticoagulant pattern | Possible lupus anticoagulant-hypoprothrombinemia syndrome | Specialized coagulation review is needed because clotting and bleeding risks can overlap. |
| High factor II activity | Increased prothrombin activity or assay-related variation | Interpret with thrombotic history, family history, and possible genetic testing when appropriate. |
A result near the lower limit should not be treated the same as a result below 10%. Mild reductions often appear with medications or transient illness. Severe reductions, especially with bleeding, deserve faster evaluation.
Low Factor II Activity
Low factor II activity means the blood sample showed reduced prothrombin clotting function. Bleeding risk rises as the level falls, but the exact risk also depends on the person’s bleeding history, other factor levels, platelet count, medications, and the type of injury or procedure.
Mildly low factor II activity often causes no day-to-day bleeding. It becomes more important before surgery, childbirth, invasive procedures, dental extraction, or trauma. Severe factor II deficiency can cause prolonged bleeding, large bruises, soft tissue bleeding, heavy menstrual bleeding, umbilical cord bleeding in newborns, or bleeding after surgery.
Common causes of low factor II activity include:
- warfarin or other vitamin K antagonist therapy
- vitamin K deficiency from poor intake, malabsorption, bile flow problems, or prolonged antibiotic exposure
- liver disease, because the liver makes prothrombin
- disseminated intravascular coagulation, where clotting factors are consumed
- severe illness with multiple coagulation abnormalities
- inherited factor II deficiency
- acquired inhibitors or immune-mediated prothrombin clearance
- direct Xa inhibitors or direct thrombin inhibitors causing falsely low activity in some clot-based assays
Warfarin lowers vitamin K-dependent clotting factors, including factors II, VII, IX, and X. Factor II has a longer half-life than factor VII, so its level falls and recovers more slowly. This is one reason INR changes during starting or stopping warfarin do not always match full factor II recovery immediately. People taking warfarin should interpret factor II activity only with the prescribing clinician or anticoagulation clinic.
Vitamin K deficiency often lowers several factors together. Factor VII tends to fall early because it has a shorter half-life, while factor II reflects a more sustained reduction. If vitamin K deficiency is suspected, clinicians often review diet, fat absorption, bile duct disease, antibiotics, and other test results. A related vitamin K evaluation can include vitamin K testing or indirect markers when available.
Liver disease can lower factor II because prothrombin is made in the liver. In advanced liver disease, factor II often falls along with other clotting factors and proteins. That is why abnormal factor II activity is sometimes interpreted with a hepatic function panel, albumin, bilirubin, platelet count, fibrinogen, and clinical signs such as jaundice, fluid retention, or easy bleeding.
Inherited factor II deficiency is much rarer than acquired factor II reduction. It is usually autosomal recessive, meaning a person typically needs two altered copies of the gene to have a more significant deficiency. Heterozygous carriers often have activity near the lower range or around half-normal and usually have no bleeding or only mild bleeding with trauma or procedures.
Severe congenital factor II deficiency is often divided into two broad types. Hypoprothrombinemia means there is too little prothrombin. Dysprothrombinemia means prothrombin is present but does not work normally. Some people have a combined pattern with reduced amount and reduced function. Specialized testing can compare factor II activity with factor II antigen to clarify the pattern.
How low is concerning?
There is no single number that predicts bleeding perfectly. Still, very low factor II activity deserves attention. Activity below about 30% is more likely to matter during trauma or surgery, and levels below about 10% are associated with more severe bleeding phenotypes in rare inherited deficiency. Some expert guidance uses target trough levels above 20 IU/dL for avoiding postoperative or spontaneous bleeding in severe factor II deficiency.
Symptoms matter as much as the number. A person with 25% activity and a history of severe surgical bleeding needs a different plan from someone with 45% activity, no bleeding history, and a clear medication explanation.
High Factor II Activity
High factor II activity means the sample showed more prothrombin clotting activity than the lab’s upper reference limit. High results are less common in everyday bleeding evaluations and are harder to interpret than low results.
Increased prothrombin levels are relevant because prothrombin is the precursor of thrombin, a major driver of clot formation. Higher prothrombin activity does not automatically mean a person will have a blood clot, but it can add to clotting tendency when combined with other risks such as prior venous thromboembolism, pregnancy, estrogen therapy, major surgery, cancer, smoking, obesity, immobility, or inherited thrombophilia.
The most familiar inherited prothrombin-related clotting risk is the prothrombin G20210A mutation. This genetic variant is linked to higher prothrombin levels and increased risk of venous clots. Standard factor II activity testing is not a reliable replacement for the genetic test. When the clinical question is inherited clot risk, clinicians usually order targeted prothrombin gene mutation testing rather than relying on factor II activity alone.
A high factor II activity result can also reflect biological variation or assay variation. Mild elevations near the upper limit often do not change care by themselves. The result carries more weight when it is clearly high, repeated, and fits a clotting history or family history.
Follow-up for high factor II activity often focuses on the whole thrombotic risk picture, not only the factor II value. That can include personal clot history, family clot history, estrogen exposure, pregnancy status, antiphospholipid antibody testing, inherited thrombophilia testing, and other risk factors. When a previous clot occurred, the evaluation also considers the clot location, provoking factors, recurrence, and whether long-term anticoagulation is needed.
A high result should not lead someone to start aspirin, anticoagulants, supplements, or major diet changes without professional guidance. Clot prevention depends on the cause and total risk profile. Unneeded blood-thinning treatment can create bleeding risk without clear benefit.
Testing Process and Preparation
Factor II activity is a blood test. The sample is usually collected in a light-blue-top tube containing sodium citrate, which prevents clotting in the tube while preserving the plasma for coagulation testing. The lab processes the sample into platelet-poor plasma and runs a clot-based activity assay.
Most factor II activity assays use a prothrombin time-based method. In simple terms, the lab mixes the patient’s plasma with plasma that lacks factor II, then measures how well the patient’s factor II corrects clot formation. The clotting time is compared with a calibration curve and reported as activity percentage.
Fasting is usually not required. The most important preparation is medication accuracy. The ordering clinician and lab need to know about:
- warfarin
- heparin
- direct Xa inhibitors such as apixaban, rivaroxaban, or edoxaban
- direct thrombin inhibitors such as dabigatran
- aspirin and antiplatelet drugs
- vitamin K supplements
- antibiotics taken recently or long term
- liver disease medicines
- recent plasma, prothrombin complex concentrate, or vitamin K treatment
Do not stop prescribed anticoagulants before testing unless the prescribing clinician gives clear instructions. Stopping an anticoagulant at the wrong time raises clot risk, especially in people treated for atrial fibrillation, venous thromboembolism, mechanical heart valves, or high-risk thrombophilia.
Specimen handling matters more for coagulation tests than for many routine blood tests. An underfilled citrate tube, clot in the tube, delayed processing, wrong storage temperature, or contamination from an IV line can distort results. Very high hematocrit above about 55% requires citrate adjustment because the blood-to-anticoagulant ratio changes.
Clot-based factor assays are also sensitive to anticoagulant interference. Direct Xa inhibitors and direct thrombin inhibitors can make factor activity look falsely low. Some labs use drug-neutralizing methods or alternative timing when clinically appropriate. If a surprising low result occurs while taking a direct oral anticoagulant, the medication effect should be considered before diagnosing a true factor deficiency.
Follow-Up Tests and Next Steps
Follow-up depends on whether the factor II activity is low, high, borderline, or inconsistent with the clinical picture. Repeat testing is common when a result is unexpected, especially if the person was acutely ill, taking an anticoagulant, or had a sample-quality issue.
For a low factor II activity result, clinicians often compare the pattern across related tests. PT/INR shows the extrinsic and common pathways. aPTT shows the intrinsic and common pathways. Factor V, VII, and X activity help separate vitamin K deficiency, liver disease, warfarin effect, and common pathway disorders. Fibrinogen and D-dimer help assess consumption or DIC. A mixing study helps distinguish factor deficiency from an inhibitor when PT or aPTT is prolonged.
Factor V is especially useful when liver disease or vitamin K deficiency is being considered. Factor V is made in the liver but does not depend on vitamin K. Low factor II with normal factor V can point more toward vitamin K deficiency or warfarin effect, while low factor II and low factor V activity can support impaired liver synthesis or broader consumption.
Factor VII and factor X also help clarify the pattern because they are vitamin K-dependent factors measured through related pathways. A clinician may order factor VII activity and factor X activity when PT is prolonged or when multiple vitamin K-dependent factors appear reduced.
If inherited factor II deficiency is suspected, testing may include repeat factor II activity, factor II antigen, family studies, genetic testing, and consultation with a hematologist or hemophilia treatment center. The workup should document the personal bleeding history in detail, including childhood bleeding, dental extraction bleeding, surgical bleeding, heavy menstrual bleeding, postpartum bleeding, nosebleeds, joint bleeding, and bleeding after injuries.
If high factor II activity raises concern for clot risk, the next step is usually a thrombosis-focused history and targeted testing. Genetic testing for the prothrombin G20210A mutation is separate from activity testing. Other evaluations may include factor V Leiden testing, antiphospholipid antibody testing, protein C, protein S, antithrombin, and assessment of acquired clot risks.
Results also matter before procedures. A person with known low factor II activity should tell the surgeon, dentist, obstetric team, or proceduralist before planned care. Some patients need a written bleeding plan that explains target factor levels, possible use of prothrombin complex concentrate or plasma, tranexamic acid for mucosal bleeding, and when to contact hematology.
When Results Need Prompt Attention
Factor II activity results need prompt medical attention when they match active bleeding, a very prolonged PT/INR or aPTT, very low activity, or signs of a serious underlying condition. The urgency is higher when the person takes anticoagulants, has liver disease, is pregnant or recently delivered, is preparing for surgery, or has a history of severe bleeding.
Seek urgent care for symptoms such as:
- bleeding that does not stop with firm pressure
- vomiting blood or passing black, tarry, or bloody stool
- blood in urine with clots or significant pain
- severe headache, confusion, weakness, or vision changes after injury or while anticoagulated
- large, rapidly expanding bruises or painful swelling
- heavy menstrual bleeding with dizziness, fainting, or shortness of breath
- bleeding after surgery, childbirth, dental extraction, or trauma
- newborn umbilical stump bleeding or unexplained severe bruising
A low factor II result should also be reviewed quickly before an invasive procedure. Even moderate deficiency can become important when tissue injury is expected. Dental extraction, tonsil surgery, gastrointestinal biopsy, childbirth, major surgery, and regional anesthesia require special planning in people with meaningful clotting factor deficiency.
People with high factor II activity should seek urgent care for possible clot symptoms rather than focusing only on the lab number. Warning signs include one-sided leg swelling or pain, sudden shortness of breath, chest pain that worsens with breathing, coughing blood, sudden weakness on one side of the body, trouble speaking, or sudden severe headache. These symptoms require emergency evaluation.
For non-urgent abnormal results, the most useful next step is a structured review with the ordering clinician. Bring a list of medicines and supplements, any recent anticoagulant doses, history of liver or digestive disease, recent antibiotics, family bleeding or clotting history, prior surgery outcomes, and any pregnancy-related bleeding or clotting events. That context often explains more than the number alone.
References
- Factor II, Activity (Prothrombin) | ARUP Laboratories Test Directory 2025 (Laboratory Test Directory)
- Coagulation Factor II Activity Assay, Plasma 2025 (Laboratory Test Directory)
- RCPA – Coagulation factor levels 2024 (Laboratory Manual)
- Hemostasis and Thrombosis Testing | ARUP Consult 2025 (Clinical Review)
- Rare inherited coagulation disorders: no longer orphan and neglected 2024 (Review)
- Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders 2023 (Review)
Disclaimer
This article is for educational use and does not replace care from a qualified healthcare professional. Factor II activity results need interpretation with symptoms, medications, bleeding or clotting history, and related coagulation tests. Anyone with active bleeding, symptoms of a blood clot, or abnormal results before surgery, childbirth, or an invasive procedure should seek medical guidance promptly.
